Article Type

Original Study


Objective To study the relationship between cyclin D1 G870A polymorphism and hepatocellular carcinoma (HCC) in Egyptian patients. Background Cyclin D1, encoded by the gene CCND1, is a regulatory protein in the cell cycle transition from G1 phase to S phase. A common polymorphism (G870A) in the exon 4 of CCND1 gene affects splicing of the CCND1 transcript and may cause uncontrollable cellular growth. Therefore, the CCND1 G870A polymorphism may influence an individual's susceptibility to the development of certain tumors, which may include HCC. Patients and methods This study was carried out on 100 participants: 60 patients with HCC and 40 healthy age-matched and sex-matched volunteers. All participants underwent full history, liver profile, α-fetoprotein, and cyclin D1 G870A polymorphism assessment, which was done by PCR-restriction fragment length polymorphism assay. Results The CCND1 genotype distribution among patients with HCC was significantly different from that of healthy controls (P = 0.000). Compared with the wild-type GG genotype, both the variant AA and AA+GA genotype and the A allele were associated with risk of HCC [odds ratio (OR): 64; 95% confidence interval (CI): 6.67–614.2;P = 0.000; OR: 19.67; 95% CI: 2.4–160.94;P = 0.000; and OR: 4.03; 95% CI: 2.2–7.41;P = 0.000, respectively]. Moreover, there is no significant correlation between the different cyclin D1 genotypes and clinicopathologic features of HCC. Conclusion Our results suggest that the CCND1 G870A polymorphism is associated with an increased risk of HCC in our Egyptian population.